Company news
Quantum Biopharma Ltd. Subordinate Voting Shares news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Quantum BioPharma Ltd. Announces Corporate Updates
October 29, 2025
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication
October 23, 2025
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
October 20, 2025
KILL QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm
October 14, 2025
KILL Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QNTM
October 14, 2025
Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group
October 14, 2025
Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QNTM
October 9, 2025
QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm
October 9, 2025
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
October 8, 2025
Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View
October 7, 2025
Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
October 3, 2025
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial
October 2, 2025
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
October 1, 2025
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
September 29, 2025
Quantum BioPharma Announces Corporate Updates
September 25, 2025
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
September 24, 2025
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity(TM), that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
September 18, 2025
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1: 30 PM PT
September 12, 2025
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
September 10, 2025
Quantum BioPharma Announces Update to Previously Announced Private Placement
August 11, 2025
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
August 11, 2025
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
August 8, 2025
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt
August 7, 2025
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
August 5, 2025
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
August 4, 2025
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
July 31, 2025
Quantum BioPharma Makes Strategic Investment in GameStop Corp.
July 22, 2025
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
July 8, 2025
Quantum BioPharma Announces Private Placement of 12 Class A Multiple Voting Shares at a Price of $50 Per Share
June 27, 2025
Quantum BioPharma Announces Private Placement
June 27, 2025
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
June 26, 2025
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
June 18, 2025
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
June 17, 2025
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
June 13, 2025
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
June 10, 2025
Quantum BioPharma Clarifies It Has Not Changed Its Name
June 3, 2025
iNGEN? CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
June 2, 2025
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
May 30, 2025
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
May 29, 2025
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
May 28, 2025
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
May 21, 2025
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
May 20, 2025
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
May 19, 2025
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
May 12, 2025
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
May 5, 2025
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4: 30 p.m. Eastern Time
April 24, 2025
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
April 22, 2025
Quantum BioPharma Corporate Update
April 17, 2025
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
April 14, 2025
Decks
- Quantum BioPharma — Investor Presentation (September 2026)
Investor deck · 27 slides · September 2026